Aktuellt
SENASTE
Redeye maintains its view of Orexo and the valuation of SEK 80 per share, after the report today. The company is finding ways to slow down the decline of Zubsolv revenues and to integrate the digital therapies into existing treatment models. Orexo is executing according to plan, in our view.
LÄS MER
